Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Vestibular Schwannoma
55%
Neoplasm
54%
Magnetic Resonance Imaging
52%
Dynamic Contrast-Enhanced MRI
25%
Biological Marker
25%
Neurofibromatosis Type II
24%
Contrast Medium
21%
Low Drug Dose
19%
Brain Tumor
16%
Tumor
16%
Antiangiogenic Therapy
14%
Perfusion Weighted Imaging
14%
Dynamic Susceptibility Contrast
14%
Treatment Response
11%
Macrophage
11%
Gadolinium
10%
Glioblastoma
10%
Angiogenesis
10%
Radiosurgery
9%
Diffusion MRI
9%
Central Nervous System Tumor
8%
Intracranial Tumor
8%
Brain Blood Flow
8%
Tumor Progression
8%
Gadolinium
8%
Blood Vessel Permeability
7%
Stereotactic Radiosurgery
7%
Magnetic Resonance Imaging
7%
Breast Cancer
7%
Recurrent Disease
7%
PK-11195
7%
Brain Perfusion
7%
Microsphere
7%
Scintigraphy
7%
Chemoradiotherapy
7%
Cediranib
7%
Rectum Cancer
7%
Multinuclear Magnetic Resonance Imaging
7%
Moyamoya Disease
7%
Phase I Trials
7%
Radiation Therapy
7%
Imaging Technique
7%
Superparamagnetic Iron Oxide Nanoparticle
7%
Ultrasmall Superparamagnetic Iron Oxide
7%
Radiomics
6%
Bevacizumab
6%
Blood Flow
6%
Tumor Microenvironment
5%
Selumetinib
5%
Microvessel
5%
Neuroscience
Magnetic Resonance Imaging
100%
Brain Tumor
43%
Contrast Medium
38%
Acoustic Neuroma
34%
Magnetic Resonance Imaging
21%
T2 Contrast
14%
Meningioma
14%
Pharmacokinetics
14%
Neurofibromatosis Type II
11%
Schwannoma
10%
In Vivo
9%
Diffusion MRI
8%
Arterial Spin Labeling
8%
Behavior (Neuroscience)
8%
Microsphere
7%
Perfusion Magnetic Resonance Imaging
7%
VEGF Receptors
7%
Receptor Tyrosine Kinase Inhibitors
7%
Thymostimulin
7%
Blood Brain Barrier
7%
Superior Sagittal Sinus
7%
Dynamic Susceptibility Contrast
7%
Multinuclear Magnetic Resonance Imaging
7%
Brain Tumor
7%
Microvessel
6%
Blood Vessel Permeability
6%
Bevacizumab
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
24%
Neurofibromatosis Type 2
21%
Acoustic Neuroma
19%
Breast Cancer
14%
Pentetic Acid
11%
Contrast Medium
11%
Pharmacokinetic Parameter
9%
Protein Tyrosine Kinase Inhibitor
8%
Gadolinium
7%
Recurrent Disease
7%
Rectum Cancer
7%
Vasculotropin Receptor
7%
Protein Tyrosine Kinase
7%
Moyamoya Disease
7%
Glioma
7%
Phase I Trials
7%
Microsphere
7%
Intracranial Tumor
7%
Cediranib
7%
Brain Tumor
7%
Glioblastoma
5%
Selumetinib
5%